Vericel Corporation Third Quarter 2026 - VERICEL CORP

Explicit Guidance:

• Full-Year 2026 Revenue: Raised to $344–$346 million (midpoint), representing 25% YoY growth; an increase of nearly $25 million from the start-of-year guidance.
• Full-Year 2026 EBITDA Margin: Increased to approximately 28% (up from prior 27% guidance), reflecting higher revenue and expense discipline.
• Full-Year 2026 Gross Margin: Maintained expectation of approximately 75%.
• Q4 2026 Revenue Breakdown:
  • Macy: Expecting 21% growth, approx. $102 million at midpoint. Management notes potential upside if current procedure trends continue through December.
  • Burn Care: Expecting $12 million total, composed of ~$9 million commercial revenue (split between EpiCell and Nexabrid) and $3 million Nexabrid barter procurement revenue.
• Full-Year 2026 Segment Guidance:
  • Macy: Raised to $290–$292 million (up from $284–$190 million).
  • Burn Care: Raised to approx. $54 million (up from $46–$50 million).
• Share Buybacks: $191 million remaining under authorization as of Q3 2026.

Business-Segment Outlook:

• Macy:
  • Growth Trajectory: Positioned for sustained strong growth in 2027 and beyond; internal planning anticipates continued 20%+ growth trajectory, though formal guidance for 2027 will be prudent/conservative initially.
  • Macy-Arthro: Adoption accelerating; >25% of condyle defects <4 sq cm treated via Macy-Arthro in Q3. Expect increased utilization from expanded adoption and clinical data publications in 2027.
  • Sales Force: Expanded sales force and new territories expected to drive accelerating implant growth in Q4 2026 and into 2027. New reps projected to lead implant growth in their 2nd and 3rd years.
  • Ankle Indication: Ongoing enrollment in ankle study with potential for ~$1B addressable market (20,000 patients); launch timeline pending.
• Burn Care:
  • EpiCell: Driven by cross-selling with Nexabrid and rebranding; expected to sustain higher run rates in 2027 following record Q3 performance.
  • Nexabrid: Expansion of consistent users and ordering centers continues; commercial revenue record in Q3.
  • BART (Barter Agreement): Recognized $3M in Q3; expects additional $3M in Q4 2026 and $4M in Q1 2027, plus development-related cost offsets in 2027.
• Long-Term Targets: Management feels on track to outpace existing Long-Range Plan (LRP) targets, specifically the "half-billion by end of decade" revenue goal and high-30s% EBITDA margins.

Market and Competitive Outlook:

• UK Launch: On track for potential Macy launch in the second half of 2027; currently under NICE single technology appraisal for reimbursement/pricing. Addressable market estimated at 15,000 patients annually (several hundred million dollars).
• International Expansion: Initial market development underway for Canada and Europe; no specific launch dates provided.
• Competitive Positioning: Macy retains clear market leadership in cartilage repair (10-year track record). Management views market as underpenetrated with limited impact from new competitors like "other cartilage technologies" in Europe/UK.
• Clinical Trends: Continued shift toward restorative cartilage repair procedures supports long-term growth.

Macro / Industry Outlook:

• Regulatory: UK MHRA inspection of manufacturing facility completed in Q3; NICE acceptance of Macy for appraisal expected to establish funding guidance.
• Manufacturing: New facility operational; CapEx largely complete, contributing to improved free cash flow generation.
• FX/Supply: No specific FX impacts detailed; supply chain stability implied by successful facility ramp and record biopsies.

Strategic Initiatives:

• UK Launch Preparation: NICE appraisal process ongoing to secure reimbursement; commercial readiness for H2 2027.
• Product Innovation: Developing next-generation Macy-Arthro instruments to reduce surgical time and improve access to patella defects; continuous innovation expected to sustain surgeon engagement.
• Sales Force Expansion: Continued investment in Salesforce expansion and commercial excellence initiatives (account planning, stakeholder mapping) to unlock growth in new territories.
• Capital Allocation: Balancing opportunistic share buybacks ($191M remaining) with potential M&A/BD transactions; no constraints on BD due to strong cash flow ($18M Q3 operating cash flow, $16M free cash flow).
• Commercial Initiatives: Rebranding of EpiCell and stakeholder mapping for Nexabrid to drive standardization and consistent user adoption.

Risks and Headwinds to Outlook:

• Burn Care Variability: EpiCell revenue remains susceptible to the frequency of catastrophic burn incidents (market demand variable), though execution-driven growth is considered repeatable.
• Regulatory/Reimbursement: UK launch timing depends on NICE appraisal outcome and funding guidance.
• Product Adoption: Macy-Arthro penetration into smaller defects and patella requires continued surgeon training and instrument optimization.
• Guidance Conservatism: Management intends to maintain a "prudent" or "conservative" approach to formal 2027 guidance starting points, potentially lagging internal expectations initially.

Management Tone on the Future:

• Confidence: Highly confident ("exceptionally well positioned," "bullish," "on track to outpace").
• Momentum: Highlights "surging engagement," "record" execution in Q3, and "strong start" to Q4.
• Strategic Shift: Noting a transition from "investment phase" to "growth and cash generation phase" with margins expanding to the mid-70s (gross) and high-20s/low-30s (EBITDA).
• Long-Term View: Belief that the company is outpacing midterm targets; expects sustained high revenue growth and profitability in 2027 and beyond.

Miscellaneous:

• Cash Position: $236 million in cash and investments; no debt.
• Free Cash Flow: >$45 million generated YTD 2026.
• Clinical Data: New publications highlight durable outcomes (13.6-year follow-up for OUS) and surgical advantages of Macy-Arthro; registry expansion planned for 2027.